PRF-110
Post-operative pain relief following bunionectomy
Key Facts
About PainReform
PainReform is dedicated to developing innovative, non-opioid pain management solutions by leveraging its proprietary extended-release drug delivery platform. Its primary mission is to address the significant unmet need for effective, long-lasting post-operative analgesia, thereby reducing reliance on systemic opioids and their associated risks. The company's most advanced candidate, PRF-110, has demonstrated promising results in clinical trials for bunionectomy and hernia repair. PainReform's strategy centers on advancing its pipeline through clinical development and seeking strategic partnerships for commercialization.
View full company profileAbout PainReform
PainReform is dedicated to developing innovative, non-opioid pain management solutions by leveraging its proprietary extended-release drug delivery platform. Its primary mission is to address the significant unmet need for effective, long-lasting post-operative analgesia, thereby reducing reliance on systemic opioids and their associated risks. The company's most advanced candidate, PRF-110, has demonstrated promising results in clinical trials for bunionectomy and hernia repair. PainReform's strategy centers on advancing its pipeline through clinical development and seeking strategic partnerships for commercialization.
View full company profile